Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP Group Swings To Loss In First-Half On Reduction In Portfolio Gains

Wed, 25th Jul 2018 09:39

LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.

The intellectual property-based business developer said pretax loss for six months to the end of June was GBP21.6 million, swinging from a pretax profit of GBP16.7 million for the same period the year previously.

This was due to a change in the fair value of its equity and debt investments to GBP700,000, from a fair value gain of GBP28.5 million the year before.

Licensing income more than halved to GBP800,000 million from GBP3.0 million the year before, while the fair value of its portfolio nearly doubled to GBP1.16 billion from GBP663.0 million year-on-year.

The single largest portfolio company fair value increase during the period was Diurnal Group PLC in the Life Sciences sector.

The London-listed pharmaceutical company hit a major milestone this year, moving it from a development company onto marketing and sales, after Infacort medicine was approved for marketing by the European Commission. An increase in the share price of Diurnal resulted in a fair value increase of GBP10.2 million to IP Group.

During the first half of 2018, IP Group said it deployed GBP46.9 million of capital into 41 portfolio companies and projects.

"The underlying performance of the group's portfolio has been robust in the first half with a number of our companies completing both major fundraisings and collaborations," said Chief Executive Alan Aubrey.

"The group remains excited by the opportunities within the portfolio and we look to the second half of the year and beyond with confidence," added Aubrey.

Shares in IP Group were trading 2.6% lower on Wednesday at 126.96 pence each.

More News
11 Oct 2021 19:51

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

Read more
14 Sep 2021 17:46

TRADING UPDATES: Strong annual results from Springfield, Fiske

TRADING UPDATES: Strong annual results from Springfield, Fiske

Read more
13 Sep 2021 20:23

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

Read more
7 Sep 2021 16:25

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
1 Sep 2021 19:34

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

Read more
28 Jul 2021 18:07

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

Read more
12 Jul 2021 10:10

Diurnal agrees special protocol with FDA for Chronocort study

(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or modified-release hydrocortisone, for the design, endpoints and statistical analysis approach of a pivotal study of the product, for the treatment for congenital adrenal hyperplasia (CAH).

Read more
2 Jul 2021 10:02

Diurnal gets UK approval for 'Efmody' treatment

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for 'Efmody', or hydrocortisone modified-release hard capsules, as treatment for adult and adolescent patients with the rare congenital adrenal hyperplasia (CAH) condition.

Read more
2 Jul 2021 10:01

Diurnal gets UK approval for Efmody drug following EU authorisation

Diurnal gets UK approval for Efmody drug following EU authorisation

Read more
29 Jun 2021 17:10

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

Read more
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
28 May 2021 19:41

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

Read more
12 May 2021 15:30

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

Read more
23 Apr 2021 12:56

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

Read more
23 Apr 2021 10:31

Diurnal granted European patent for Alkindi

(Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.